Minakem Generic APIs Minakem Generic APIs

X

Find Florbetaben manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

EU WC

EU WC

0

Listed Suppliers

Listed Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Florbetaben F 18
Also known as: Neuraceq, Florbetaben (18f), Florbetaben f18, Florbetaben, Florbetaben f 18, 18f-florbetaben
Molecular Formula
C21H26FNO3
Molecular Weight
358.4  g/mol
InChI Key
NCWZOASIUQVOFA-FWZJPQCDSA-N
FDA UNII
TLA7312TOI

Florbetaben (18F) is a stilbene derivative labeled with the positron-emitting isotope fluorine F 18, that may be used for positron emission tomography (PET) detection of beta-amyloid neuritic plaques and other amyloid protein deposits. Upon administration, F 18-florbetaben exhibits differential retention in regions that contain certain amyloid deposits. Differences in signal intensity between tissues showing specific and non-specific uptake of F 18-florbetaben allows for the detection of amyloid neuritic plaques in patients being evaluated for Alzheimer's disease, and potentially the detection of amyloid deposits in amyloidosis.
Florbetaben f-18 is a Radioactive Diagnostic Agent. The mechanism of action of florbetaben f-18 is as a Positron Emitting Activity.
1 2D Structure

Florbetaben F 18

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-[(E)-2-[4-[2-[2-(2-(18F)fluoranylethoxy)ethoxy]ethoxy]phenyl]ethenyl]-N-methylaniline
2.1.2 InChI
InChI=1S/C21H26FNO3/c1-23-20-8-4-18(5-9-20)2-3-19-6-10-21(11-7-19)26-17-16-25-15-14-24-13-12-22/h2-11,23H,12-17H2,1H3/b3-2+/i22-1
2.1.3 InChI Key
NCWZOASIUQVOFA-FWZJPQCDSA-N
2.1.4 Canonical SMILES
CNC1=CC=C(C=C1)C=CC2=CC=C(C=C2)OCCOCCOCCF
2.1.5 Isomeric SMILES
CNC1=CC=C(C=C1)/C=C/C2=CC=C(C=C2)OCCOCCOCC[18F]
2.2 Other Identifiers
2.2.1 UNII
TLA7312TOI
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 18f-bay94-9172

2. 18f-florbetaben

3. 4-(n-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene

4. Bay 94-9172

5. Bay94 9172

6. Bay94-9172

7. Florbetaben

2.3.2 Depositor-Supplied Synonyms

1. Neuraceq

2. Florbetaben (18f)

3. Florbetaben F18

4. Florbetaben

5. Florbetaben F 18

6. 18f-florbetaben

7. Unii-tla7312toi

8. 902143-01-5

9. Florbetaben ((sup 18)f)

10. Florbetaben (18f) [inn]

11. Bay94-9172

12. Bay 94-9172

13. Chebi:79033

14. Florbetaben F18 [usan]

15. Bay-949172

16. 18f-bay94-9172

17. Tla7312toi

18. Av-1

19. 4-((1e)-2-(4-(2-(2-(2-((sup 18(f))fluoroethoxy)ethoxy)ethoxy)phenyl)eth-1-en-1-yl)-n-methylaniline

20. 4-[(e)-2-[4-[2-[2-(2-(18f)fluoranylethoxy)ethoxy]ethoxy]phenyl]ethenyl]-n-methylaniline

21. Neuraceq (tn)

22. Florbetaben ((18)f)

23. Florbetaben 18f [inn]

24. Florbetaben (f-18)

25. Chembl566752

26. Gtpl7769

27. Schembl11301755

28. Florbetaben F 18 [mi]

29. Dtxsid20238065

30. Florbetaben(18f) [jan]

31. Bdbm50485236

32. Florbetaben (18f) [who-dd]

33. Bay94 9172

34. Db09148

35. Florbetaben (18f) (jan/usan/inn)

36. Florbetaben F-18 [orange Book]

37. [18f]bay 94-9172

38. Zk-6013443

39. Q17014149

40. 4-[(e)-2-[4-[2-[2-(2-fluoranylethoxy)ethoxy]ethoxy]phenyl]ethenyl]-n-methylaniline

41. 4-{(e)-2-[4-(2-{2-[2-((18)f)fluoroethoxy]ethoxy}ethoxy)phenyl]ethenyl}-n-methylaniline

2.4 Create Date
2006-10-26
3 Chemical and Physical Properties
Molecular Weight 358.4 g/mol
Molecular Formula C21H26FNO3
XLogP34.2
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count5
Rotatable Bond Count12
Exact Mass358.192206 g/mol
Monoisotopic Mass358.192206 g/mol
Topological Polar Surface Area39.7 Ų
Heavy Atom Count26
Formal Charge0
Complexity364
Isotope Atom Count1
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count1
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Florbetaben is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate -amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimers Disease (AD) and other causes of cognitive decline.


FDA Label


This medicinal product is for diagnostic use only.

Neuraceq is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimers disease (AD) and other causes of cognitive impairment. Neuraceq should be used in conjunction with a clinical evaluation.

A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Following intravenous administration, Neuraceq crosses the blood brain barrier and shows differential retention in brain regions that contain -amyloid deposits. Differences in signal intensity between brain regions showing specific and non-specific Neuraceq uptake form the basis for the image interpretation method.


5.2 FDA Pharmacological Classification
5.2.1 Active Moiety
FLORBETABEN F-18
5.2.2 FDA UNII
TLA7312TOI
5.2.3 Pharmacological Classes
Radioactive Diagnostic Agent [EPC]; Positron Emitting Activity [MoA]
5.3 ATC Code

V09AX06


V - Various

V09 - Diagnostic radiopharmaceuticals

V09A - Central nervous system

V09AX - Other central nervous system diagnostic radiopharmaceuticals

V09AX06 - Florbetaben (18F)


5.4 Absorption, Distribution and Excretion

Absorption

Ten minutes after intravenous bolus injection of 300 MBq of Neuraceq in human volunteers, approximately 6% of the injected radioactivity was distributed to the brain. Florbetaben F 18 plasma concentrations declined by approximately 75% at 20 minutes post-injection, and by approximately 90% at 50 minutes.


Route of Elimination

At 12 hours post-administration, approximately 30% of the injected radioactivity had been excreted in urine.


5.5 Metabolism/Metabolites

In vitro studies show that metabolism of florbetaben is predominantly catalyzed by CYP2J2 and CYP4F2. Almost all F18 radioactivity in urine was excreted as polar metabolites of florbetaben F18 and only trace amounts of florbetaben F18 were detected.


5.6 Biological Half-Life

1 hr


5.7 Mechanism of Action

Florbetaben F18 is a F18-labeled stilbene derivative, which binds to -amyloid plaques in the brain. The F 18 isotope produces a positron signal that is detected by a PET scanner.


Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY